Title: County by county estimation of possible deaths averted, infections averted, and cost savings of overdose prevention centers in the United States from July 2019-June 2025.

Authors: Katie Bailey, PhD, MPA[1], Rohith Palli, MD, PhD[2], Mike Sportiello, MD, PhD[3*],

1. University of California San Diego School of Medicine 9500 Gilman Dr, La Jolla, CA 92093. kkbailey@ucsd.edu
2. University of Washington Department of Biomedical Informatics and Medical Education, IT Services, and Division of General Internal Medicine. Box 358047. 850 Republican St. Seattle, WA 98195. Rpalli@uw.edu
3. Emory University School of Medicine Department of Medicine. 49 Jesse Hill Dr. SE, Suite 491, Atlanta, GA 30303. Msporti@emory.edu. ***Corresponding author.**

Abstract

Overdose prevention centers (OPCs), also known as safer injection facilities (SIFs) or supervised consumption sites (SCSs), are a service that allows people to obtain sterile supplies to use their own drugs in a safe environment that is monitored by professionals trained in overdose response and harm reduction. Though still illegal under federal law in the U.S. ("Maintaining Drug-Involved Premises"; "United States v. Safehouse", 2021), many legal or quasi-legal (including some in the U.S.) OPCs have operated since the 1980s. Using CDC overdose death estimates and U.S. Census Bureau population data, we developed a retrospective, scenario-based modeling tool, estimating that 1,329-5,316 deaths could have been averted between July 2019 and June 2025 if 1 out of 100-400 injections had taken place at an OPC. Under these assumptions, 26-105 HIV transmissions and 5,723-22,892 Hepatitis C transmissions could have been averted. Factoring in both discounted lifetime costs to treat those infections as well as the statistical value of deaths averted, $11.9-47.7 billion could have been saved. These data support OPCs as one viable public health intervention to avert deaths and avoid infections. We created a web application that allows users to explore county-level model results and alter model assumptions, including variables like the percent of injections that occur at an OPC.

Introduction

Overdose prevention centers (OPCs), also known as supervised consumption sites (SCSs) or safer injection facilities (SIFs) when designed primarily for people who inject drugs (PWID), offer a monitored setting where people can use pre-obtained drugs with access to sterile supplies, staff trained in overdose response, and referrals to medical, behavioral health, and social services. Many legal or quasi-legal OPCs have operated in multiple countries since the 1980s, including some in the U.S., although they are not clearly authorized under U.S. federal law (Beletsky et al., 2018; "Maintaining Drug-Involved Premises"; "United States v. Safehouse", 2021). Across these settings, overdoses have been managed on-site, with no deaths reported in supervised consumption spaces, in large part due to rapid intervention with naloxone, an opioid overdose reversal agent, and respiratory support such as supplemental oxygen or bag-mask ventilation (Suen et al., 2023).

Research from Canada suggests that OPCs can reduce overdose-related harms, including mortality (Gariepy et al., Sites de consommation supervisee et mortalite par surdose a l'echelle de la population : revue systematique des donnees recentes, 2016-2024./2025). For example, a study of Vancouver's first OPC found a 35% reduction in overdose deaths in the surrounding area compared to smaller declines in the rest of the city (Marshall et al., 2011). In Toronto, spatial analyses estimated that approximately two overdose deaths per 100,000 people were averted annually in areas closest to OPCs (Rammohan et al., 2024). Additional analyses from Ontario found more favorable overdose mortality trends and fewer overdose-related adverse outcomes in areas with greater OPC

presence or capacity (Panagiotoglou & Lim, 2022; T. Robinson et al., 2024; Yeung et al., 2023), and individual- and population-level studies from Vancouver and Alberta have similarly suggested that greater OPC engagement is associated with lower overdose mortality and related harms (Kennedy et al., 2019; Marshall et al., 2021).

Findings, however, have not been uniformly favorable. A controlled interrupted time-series study from Ontario and a linked cohort analysis from Toronto reported null, mixed, or limited short-term associations between OPC availability and opioid-related mortality, acute care use, or other health outcomes at the population level (Day et al., 2026; Tessa Robinson et al., 2024). These mixed findings likely reflect differences in study design, follow-up time, geographic scale, service intensity, and the difficulty of isolating OPC effects amid a rapidly evolving overdose crisis (Gariepy et al., Sites de consommation supervisee et mortalite par surdose a l'echelle de la population : revue systematique des donnees recentes, 2016-2024./2025). In the U.S., evidence remains more limited due to legal restrictions, but includes observational studies of an unsanctioned OPC (Kral et al., 2020), the first two publicly recognized OPCs in New York City (Harocopos et al., 2022), and a sanctioned San Francisco-based OPC that has since closed (Suen et al., 2023), with each reporting high utilization, numerous overdose events managed on-site, and no observed fatal overdoses within supervised settings.

Modeling studies have also projected meaningful public health and economic benefits of OPC implementation in specific Canadian and U.S. cities, including estimated reductions in overdose deaths, infectious disease transmission, ambulance and

71 emergency department utilization, and health care costs, with resulting favorable cost-
72 effectiveness estimates (Andresen & Boyd, 2010; Bayoumi & Zaric, 2008; Irwin et al., 2016;
73 Irwin et al., 2017; Jozaghi et al., 2013). A recent systematic review of economic evaluations
74 similarly concluded that OPC implementation was consistently associated with favorable
75 economic outcomes across North American settings (Behrends et al., 2024). Importantly,
76 however, OPCs may be better aligned with some patterns of drug use and overdose risk
77 than others. Most evidence on OPC outcomes has focused on opioid-related overdose and
78 supervised injection drug use, while overdose risk in the U.S. increasingly reflects non-
79 injection routes of use, including smoking (Ciccarone et al., 2024; Eger et al., 2024;
80 Karandinos et al., 2024; Kral et al., 2021), as well as growing stimulant involvement (Tanz et
81 al., 2025). Although some OPCs are adapting to include ventilated spaces for inhalation
82 (OnPoint, 2025), these services have not traditionally been part of the OPC model. As a
83 result, the impact of OPCs likely varies depending on local patterns of drug use and the
84 extent to which site services align with the needs of people at highest risk of overdose.
85 We build on previous literature to explore the potential impact of OPC
86 implementation across U.S. communities while accounting for variation in local conditions
87 and implementation assumptions (Harocopos et al., 2022; Kral et al., 2020). To do so, we
88 developed a retrospective, scenario-based modeling tool to estimate a range of possible
89 public health and economic outcomes if OPCs had been implemented across U.S.
90 counties between July 2019 and June 2025. Specifically, we estimate potential deaths, HIV
91 and Hepatitis C virus (HCV) infections, and downstream economic burden averted under

varying assumptions about key implementation and utilization parameters, such as frequency of OPC use among people who inject drugs (PWID). Because the model is primarily based on assumptions related to supervised injection of opioids, these estimates are likely most applicable to settings where opioid injection was a major driver of overdose risk. Rather than estimating a single nationwide causal effect of OPCs, we developed an interactive web application that enables policymakers, advocates, and other stakeholders to explore how OPC implementation might have influenced county-level public health outcomes. We further illustrate the application of this tool through three county-level case studies, highlighting how estimated outcomes vary across diverse settings and under different implementation assumptions.

Methods

Provisional 12-month ending drug overdose deaths by county were obtained from the National Center for Health Statistics for June of each year from 2020 through 2025 (Ahmad et al., 2026); each estimate represents deaths occurring over the preceding 12 months (July–June), yielding non-overlapping annual periods. Population and age data were downloaded from the U.S. Census Bureau. For this analysis, we assumed 1.5% of adults were PWID per previous estimates (Bradley et al., 2026; Bradley et al., 2023). For each PWID, we estimated 508.8 injections per year, or just under 1.5 injections based on prior estimates (Bradley et al., 2026; Bradley et al., 2023).

Deaths averted

Deaths averted were calculated by assuming the total number of injections stayed constant. Secondly, we assumed that deaths cannot occur after an injection in the OPC, as no reported overdose death has ever occurred in an OPC. The *injections that would occur at an OPC* were calculated by modeling 0.25%, 0.5%, 0.75%, or 1% of injections taking place at the OPC. This led to the following calculation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * Overdose\ deaths = Deaths\ averted$$

With the fraction on the left simplifying to the frequency of total injections in the OPC, multiplied by the number of deaths. If all the injections took place at the OPC, the leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the whole left term would simplify to 0 and no deaths would be averted.

HCV transmissions averted

HCV is a highly transmissible virus in the setting of shared needle use (Pouget et al., 2012), leading to significant morbidity, mortality, and health expenditures (Stepanova & Younossi, 2017). While curative therapy now exists, it is expensive and requires weeks-long adherence, which can be difficult for many PWID as they are disproportionately housing-insecure and have persistent barriers to healthcare engagement (Austin et al., 2022; Kimball et al., 2024). Similar to deaths averted, due to the supply of sterile drug use equipment including needles and cottons, transmission of HCV has never been documented at an OPC. Natural incidence of HCV within PWID varies widely, with study estimates varying from 0.51 to 47 per 100 person years (Gutfraind et al., 2015). For this

analysis, we used a lower-end estimate of 10 per 100 person years (Gutfraind et al., 2015), leading to the following equation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HCV\ incidence = HCV\ transmissions\ averted$$

HIV transmissions averted

Though the vast majority of HIV is not transmitted through injection drug use, it is still a meaningful target of HIV transmission prevention efforts in the U.S. (Centers for Disease & Prevention, 2024). Others have calculated the incidence of HIV transmission in groups of PWID, stratifying their use as low, medium, and high risk depending on factors including how often they share needles with people they know and alternatively with strangers (Jarlais et al., 2022). Using these incidences, we calculated HIV transmissions averted with the following equations:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [low\ risk]$$

$$= HIV\ transmissions\ averted\ [low\ risk]$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [medium\ risk]$$

$$= HIV\ transmissions\ averted\ [medium\ risk]$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [high\ risk]$$

$$= HIV\ transmissions\ averted\ [high\ risk]$$

149 ### Costs averted

150 Substantial health care dollars are spent treating preventable diseases. Infectious
151 diseases can be prevented with appropriate education and low-cost materials. Others
152 have estimated the discounted lifetime cost of an HIV infection to be $448,095 after
153 adjusting for inflation (Schackman et al., 2015). We calculated the discounted lifetime cost
154 of an HIV infection with the following equation:

155 $$\$448{,}095 * averted\ HIV\ transmission = Discounted\ cost\ of\ an\ averted\ HIV\ infection$$

156 Similar work has been done to calculate the discounted lifetime cost of HCV,
157 calculated to $339,968 (after adjusting for inflation) (Liu et al., 2016).

158 $$\$339{,}968 * averted\ HCV\ transmission = Discounted\ cost\ of\ an\ averted\ HCV\ infection$$

159 Finally, we calculated the total economic costs of the lives lost to overdose, using
160 $7.5 million as the statistical value of life, consistent with conservative estimates used by
161 U.S. federal agencies (Federal Emergency Management), giving the following equation:

162 $$\$7{,}500{,}000 * Averted\ deaths = Statistical\ costs\ of\ deaths\ averted$$

163 In this work, total costs would include adding up both the discounted costs of HIV
164 and HCV infections as well as statistical costs of deaths averted:

165 $$Discounted\ infectious\ costs + Statistical\ costs\ of\ daths\ averted = Total\ costs\ averted$$

166 Of note, total costs averted do not include indirect benefits, such as potential
167 reductions in HIV and HCV transmission outside of the OPC or decreased emergency
168 service utilization associated with on-site overdose management.

169 All analysis was performed using R and can be found publicly available here:
170 https://github.com/sportiellomike/OPC-analysis-code.

Web application

A free web application ("OPC Data Explorer") was created using the Shiny infrastructure and written in R (Alboukadel, 2023; Aron et al., 2025; Edzer, 2018; Edzer & Roger, 2023; Elio, 2025; Garnier et al., 2024; Gregory et al., 2023; Hadley, 2007; Hadley, Lionel, et al., 2025; Hadley et al., 2019; Hadley, Thomas Lin, et al., 2025; Jeffrey, 2024; Jeroen, 2025; Kyle & Matt, 2025; Mark et al., 2017; Paolo Di, 2024; Scott et al., 2023; Sergei, 2024; Team, 2025; Teun van den, 2025; Tyson et al., 2025; Winston, 2021; Winston et al., 2024; Yihui et al., 2024). All code for the data explorer web application is free and open source and can be found here: https://github.com/sportiellomike/OPC-data-explorer. The most up to date version of the web application itself can be found here: https://sportiellomike.shinyapps.io/OPC-data-explorer/. Minimal assistance in coding was provided by generative artificial intelligence (AI) using claude-3.5-sonnet. All additions provided by AI were manually checked at the time of coding for both function and syntax. Generative AI was not utilized to create or manipulate any figure.

Results

Analytic results

Estimates of potential deaths averted are shaped by assumptions regarding the percentage of injections that occur at an OPC (Table 1). At the low end, assuming 0.25% of injections occurred at OPCs across U.S. counties, (1 injection out of 400, or one injection every 287 days [400/(508.8/365)]) per PWID, an estimated 1,329 deaths may have been

191 averted nationally. At the higher end of 1% of injections occurring at an OPC, 5,316 deaths

192 may have been averted.

193 *Table 1: Summary table of estimated overdose deaths, infectious diseases, and downstream economic burden*

194 *averted under modeled Overdose Prevention Centers implementation across U.S. counties, July 2019-June 2025*

Percent of injections occurring at OPC	0.25%	0.5%	0.75%	1%
Deaths averted	1328.91	2657.82	3986.73	5315.64
HCV infections averted	5722.9	11445.98	17168.98	22891.97
HIV-low infections averted	11.45	22.89	34.34	45.78
HIV-medium infections averted	26.33	52.65	78.98	105.30
HIV-high infections averted	32.05	64.10	96.15	128.20
Discounted lifetime cost infections (billions of dollars)	1.96	3.91	5.87	7.83
Cost of life (billions of dollars)	9.97	19.93	29.90	39.87
Total costs (billions of dollars)	11.92	23.85	35.77	47.70

195

196 Estimates of HCV infections averted range from 5,723 to just under 22,892 (Table 1),

197 and dozens of HIV transmissions may have been averted (Table 1). Across all OPC

198 utilization scenarios, estimated downstream economic burden potentially averted was in

199 the range of billions to tens of billions of dollars.

200 Even under more limited implementation scenarios, such as restricting OPCs to the

201 top 50 counties with the largest estimated populations of PWID (Table 2) or those with the

202 50 highest rates of overdose deaths per capita (Table 3), projected impacts remained

203 substantial. A list of these counties can be found in supplementary Tables 1 and 2

204 respectively.

205 *Table 2: Estimated overdose deaths, infectious diseases, and downstream economic burden averted under*
206 *modeled Overdose Prevention Centers implementation across the 50 U.S. counties with the greatest number of people*
207 *who inject drugs per capita, July 2019-June 2025*

Percent of injections occurring at OPC	0.25%	0.5%	0.75%	1%
Deaths averted	402.49	804.97	1207.46	1609.94
HCV infections averted	1738.93	3477.85	5216.78	6955.71
HIV-low infections averted	3.48	6.96	10.43	13.91
HIV-medium infections averted	8.00	16.00	24.00	32.00
HIV-high infections averted	9.74	19.48	29.21	38.95
Discounted lifetime cost of infections (billions of dollars)	0.59	1.19	1.78	2.38
Cost of life (billions of dollars)	3.02	6.04	9.06	12.07
Total costs (billions of dollars)	0.59	1.19	1.78	2.38

208

209 *Table 3: Estimated overdose deaths, infectious diseases, and downstream economic burden averted under*
210 *modeled Overdose Prevention Center implementation across 50 U.S. counties with the highest rates of overdose death*
211 *per capita, July 2019-June 2025*

Percent of injections occurring at OPC	0.25%	0.5%	0.75	1%
Deaths averted	52.77	105.54	158.31	211.08
HCV infections averted	83.82	167.64	251.46	335.28
HIV-low infections averted	0.17	0.34	0.50	0.67
HIV-medium infections averted	0.39	0.77	1.16	1.54
HIV-high infections averted	0.47	0.94	1.41	1.88
Discounted lifetime cost of infections (millions of dollars)	0.03	0.06	0.09	0.11

Cost of life (billions of dollars)	0.40	0.79	1.19	1.58
Total costs (billions of dollars)	0.03	0.06	0.09	0.11

Web application

The open-source OPC Data Explorer interactive web application was constructed for users to investigate estimates in individual counties and create color-coded maps and tables with additional parameters not reported here (discounted costs broken down between HIV and HCV, for example) (Figure 1). The most up-to-date version can always be found at: https://sportiellomike.shinyapps.io/OPC-data-explorer/. Users can dive into the data and share downloadable figures and analytic tables.



221 *Figure 1: Overdose Prevention Center Data Explorer Web Application*

222 Case studies

223 To illustrate variations in estimates of how OPC implementation may have impacted
224 overdose, infectious disease, and economic burden across local contexts, we present
225 estimates for three counties selected to reflect different epidemiologic and geographic
226 settings. These examples are intended to demonstrate how the modeling tool may support
227 local interpretation and planning.

228 Fulton County, Georgia

229 Georgia's Fulton County is the most populous in the state and includes most of the
230 city of Atlanta and its surrounding suburbs. With approximately one million residents,
231 Fulton County has one of the highest burdens of both overdose mortality and HIV in the
232 country (Centers for Disease & Prevention, 2024), making it a useful example of a large
233 urban county where OPC implementation could have substantial impact. The county is one
234 of the priority jurisdictions in the Ending the HIV Epidemic initiative, with an estimated 2022
235 HIV incidence of 23.1 per 100,000 people (U. S. Department of Health & Human Services,
236 2026a). Similar to national trends and the case studies described below, deaths from
237 inhalation and stimulant use continue to rise in Georgia (Georgia Department of Public
238 Health, 2025a, 2025b).

239 Between July 2019 and June 2025, 1,519 Fulton County residents died from
240 overdose (Ahmad et al., 2026). Under modeled OPC implementation scenarios, we
241 estimated that 4–16 overdose deaths and 19–75 HCV infections may have been averted,

242 with minimal impact on HIV transmission (Table 4). The estimated economic value
243 associated with harms averted ranged from $35–140 million.

244 Despite being located in a non-Medicaid expansion state with comparatively lower
245 public health investment, Fulton County has developed a range of services to address
246 overdose risk (Georgia Overdose Prevention, 2026). However, the substantial burden of
247 overdose mortality indicates that existing services may not fully meet population need. In
248 this context, the modeled estimates suggest that even low levels of OPC utilization could
249 yield measurable reductions in overdose deaths and HCV infections. At the same time, the
250 modest population-level impact highlights that higher levels of OPC coverage would likely
251 be necessary to meaningfully reduce overall overdose mortality. Because the model
252 assumes a uniform prevalence of injection drug use (1.5% of the adult population), these
253 estimates may be conservative for Southern counties like Fulton, where the population of
254 people who inject drugs may be larger (Altekruse et al., 2020; Bradley et al., 2026).

255 *Table 4: County-specific estimates of overdose deaths, infectious diseases, and downstream economic burden averted*
256 *under modeled Overdose Prevention Center implementation for select counties, July 2019–June 2025[a]*

	Fulton County, GA	Monroe County, NY	San Diego County, CA
Real world overdose deaths	1519	1705	4940
Deaths averted	4-16	4-17	12-49
HCV averted	19-75	13-54	58-233
HIV-low averted	0	0	0
HIV-medium averted	0	0	0-1
HIV-high averted	0	0	0-1

Discounted lifetime cost infections (millions of dollars)	6-26	5-20	20-80
Cost of life (millions of dollars)	28-114	32-128	93-371
Total costs (millions of dollars)	35-140	37-146	113-450

[a]Data listed as ranges within each cell ranging from estimate at 1/400 injections to 1/100 injections.

Monroe County, New York

New York's Monroe County is the ninth most populous in the state with approximately 750,000 residents. The county covers a mix of urban, suburban, and rural areas with residents of the city of Rochester, the state's fourth-largest city, making up approximately 27% of the total population. Although Monroe County includes a major urban center, many overdose deaths occur outside the urban core (New York State Department of Health, 2026). While overdose death rates have declined more than national trends in recent years, the local drug supply has shifted, with increasing involvement of stimulants and xylazine (Granger & Hartman, 2025).

During the study period, 1,705 Monroe County residents died from overdose (Table 4). Under modeled OPC implementation scenarios, we estimated that between 4-17 overdose deaths may have been averted in Monroe County between July 2019 and June 2025, and 13-54 HCV infections may have been averted (Table 4). Minimal HIV infections are projected to have been averted by any scenario. Projected downstream economic burden potentially averted ranged from $37-$146 million.

New York State has been a national leader in expanding harm reduction services, including broad access to sterile syringes and the implementation of sanctioned OPCs in

New York City (New York State Department of Health, 2024). In Monroe County, these efforts are reflected in a relatively robust network of public and non-profit syringe service programs and naloxone distribution across both fixed and mobile settings (Monroe County Department of Public Health, 2026; New York State Department of Health, 2024). However, the distribution of overdose deaths outside the urban core highlights potential gaps in reach, particularly in suburban and rural areas. In this context, OPC implementation in Monroe County would likely require careful consideration of geographic need and accessibility, with potential value in complementing existing services by engaging populations not consistently reached through current approaches.

San Diego County, California

San Diego County, California, is a large urban county whose proximity to the U.S.–Mexico border shapes local drug markets and overdose risk. As part of the San Diego–Imperial Valley High Intensity Drug Trafficking Area (Office of National Drug Control, 2025), the county has long been situated within a major corridor for drug trafficking while also facing substantial burden related to overdose and infectious disease. It is also a federal priority jurisdiction in the Ending the HIV Epidemic initiative, with an estimated HIV incidence of 14.4 per 100,000 people in 2022 (U. S. Department of Health & Human Services, 2026b), and more than 55,000 residents with a history of HCV infection (Cheema et al., 2024).

During the span of this analysis, 4,940 San Diego County residents died from overdose. Under modeled OPC implementation scenarios, we estimated that between 12-

296 49 overdose deaths may have been averted in San Diego County between July 2019 and
297 June 2025. Over the same period, up to 1 HIV infection and 58-233 HCV infections may
298 have been averted. Projected downstream economic burden potentially averted ranged
299 from $113-$450 million.

300 Situated in a state with comparatively supportive harm reduction policies, San
301 Diego County's harm reduction infrastructure expanded during the study period and
302 includes multiple syringe services programs offered at fixed sites and via mobile outreach
303 and widespread naloxone distribution (Bailey et al., 2024; County of San Diego Health &
304 Human Services Agency, 2024). In this context, the modeled estimates suggest that OPC
305 implementation could provide additional reductions in overdose deaths beyond those
306 achieved through existing services and support local HCV prevention goals (Cheema et al.,
307 2024; U. S. Department of Health & Human Services, 2026b).

308 Discussion

309 While it is difficult to estimate the potential use of OPCs among PWID, this study
310 supplies a framework to assist in estimating their impact on deaths, infections, and
311 downstream economic burden. Even at very low rates of use, assuming one out of every
312 400 injections occurs at an OPC, hundreds of deaths and thousands of chronic infections
313 may have been averted over the period studied. This study also modeled OPC
314 implementation scenarios in the 50 counties with the most PWID and the 50 counties with
315 the highest per capita overdose deaths, a potentially more realistic and cost-effective
316 strategy that we estimate would have had a substantial positive impact on deaths,

317 infections, and economic burden. We highlighted three counties as brief case studies to
318 illustrate how this model can be applied in diverse local contexts

319 Our study has several limitations. Importantly, this analysis does not include
320 secondary benefits of OPCs, like the potential for participants to voluntarily engage in
321 treatment programs through referrals from OPC staff (Wood et al., 2007). It also does not
322 include potential benefits of safer drug use education, such as decreasing the rates of
323 needle sharing (Kerr et al., 2005). Lastly, this analysis does not include the potential OPC
324 benefits of connection to secondary social supports, including housing, food, healthcare,
325 or other programs. This analysis does not include any secondary detriments of OPCs,
326 though it should be noted that most of those of concern (e.g., increase in overdoses,
327 increase in new-onset illicit injection drug use) have not been borne out by studies that that
328 have actually measured these important issues of concern (Kerr et al., 2005; Wood et al.,
329 2004).

330 Another important aspect not included in this analysis is the cost to implement and
331 sustain OPCs, which would require capital and start-up costs, staff salaries, ongoing
332 supplies, and the costs of maintaining these institutions over time. Another drawback of
333 this analysis is that its estimations are retrospective rather than projected: we do not make
334 estimates regarding the impact of future OPCs, just that OPCs could have averted past
335 adverse outcomes.

336 Another limitation of this study is the uncertainty in estimating the proportion of
337 injections that would occur within OPCs if implemented. OPC utilization is likely to vary

338 across settings based on local infrastructure, service availability, and community context,
339 as well as characteristics of OPC design and implementation. In addition, the estimated
340 impact of OPCs on infectious disease transmission may depend on the existing harm
341 reduction environment; in settings with high coverage of sterile syringe access and other
342 services, the marginal reductions in HIV and HCV transmission attributable to OPCs may
343 be smaller. Drug use patterns vary widely across substances, populations, settings, and
344 interactions with healthcare and law enforcement, even within the same city or
345 neighborhood, and those who use OPCs may also be motivated to use other harm
346 reduction resources. A rate of 1 in 400 injections occurring at an OPC would likely arise
347 from a skewed distribution of use, with some individuals using the OPC frequently and
348 many using it rarely. As no previous study has estimated the likelihood of OPC uptake per
349 injection, we presented here a conservative and broad range of 0.25%-1% of injections
350 occurring at an OPC. Another source of uncertainty is the estimate of injection rates in the
351 communities without OPCs, which continues to be under debate in the literature and likely
352 varies across time, neighborhoods, drug supplies, and more. Better objective data is
353 needed to make these estimates precise.
354 Relatedly, the feasibility of OPCs has been called into question, especially for more
355 rural counties where people live less densely: would those who would use the OPC be able
356 to or desire to travel so far to an OPC? Would there be enough use of the OPC to justify the
357 cost to set up and run it? As we are not aware of any objective data to help guide the
358 estimates to these questions, we opted to treat more rural counties identically to the

359 denser counties, but as we acknowledge, county density likely plays a large role in
360 implementation decisions. As such, we presented model estimates given OPC
361 implementation in more realistic scenarios based on population size and overdose burden.
362 The density critique stems from a traditional but potentially limiting view of OPCs as
363 standalone structures with dedicated supplies and staff that are independently run.
364 However, other health care delivery models demonstrate that OPCs need not be fixed
365 spaces and may be deployed along a spectrum of permanence and independence. In
366 some communities, especially the densest, it may make sense for OPCs to exist as
367 standalone, physical structures. However, in less dense communities, OPC-type services
368 could exist within rural hospital settings, similar to how some rural specialist practices
369 operate. In even less dense settings, a mobile OPC similar to mobile dentistry and mobile
370 mammograms may be a solution (Gao et al., 2019; Reuben et al., 2002). Ultimately, our
371 data reflect not a strict analysis of a pre- and post-intervention, but the large impact minor
372 reductions in relatively unsafe drug use can have at scale.
373 As mentioned previously, inhalation overdose deaths continue to rise. This trend
374 likely reflects multiple factors, including the increasing presence of fentanyl in the drug
375 supply and shifts in routes of administration away from injection toward inhalation,
376 facilitated by the distribution of safer smoking supplies (Eger et al., 2024). Similarly, deaths
377 associated with stimulant use, also often via inhalation, continue to rise (Friedman &
378 Shover, 2023). Future OPCs should be designed to support those who smoke drugs and
379 those who use stimulants. Relative to opioid overdoses, stimulant-related overdoses

380 involve different clinical presentations and do not have a direct pharmacologic reversal
381 agent such as naloxone. As a result, OPC models that have historically focused on opioid
382 overdose response may require adaptation to effectively address stimulant and
383 polysubstance-related harms. We were not able to examine outcomes based on route of
384 administration (injection, inhalation, other) as this information is not codified in the CDC
385 overdose death dataset.

386 In the end, with these caveats in mind, we acknowledge that the total mortality and
387 morbidity of the ongoing overdose epidemic is difficult to quantify objectively, and that
388 there is often large degree of confounding in computing the effect of interventions. What
389 we proposed here is that, based on our modeling approach, OPC implementation could
390 have contributed to reductions in overdose mortality and morbidity, with effects that
391 remain meaningful even under conservative assumptions. The exact number of these
392 estimates could and should be better estimated at the local level and measured
393 objectively once an intervention is in place.

394 We invite stakeholders to use our interactive web tool to inform policy discussions
395 about whether the potential benefits of OPCs outweigh the costs in their communities,
396 recognizing that these benefits are likely to vary across settings.

397 Conclusion

398 Overall, this analysis, facilitated by our interactive, web-based modeling tool,
399 suggests that OPCs could contribute to reductions in overdose mortality and HCV
400 transmission, with impacts that vary across local contexts. By enabling stakeholders to

401 estimate potential effects in their own communities, this work highlights both the potential
402 value of OPCs and the importance of context-specific implementation. At the same time,
403 these findings underscore the need for additional empirical research to refine key
404 assumptions and improve the precision of future estimates.

405 **Acknowledgements**

406 MS was supported by NIH grant T32GM152318 during some of the time of this work. KB is
407 supported by NIDA grant T32DA023356.

408

References

Ahmad, F. B., Anderson, R. N., Cisewski, J. A., Rossen, L. M., & Sutton, P. (2026). County-level provisional drug overdose death counts. https://doi.org/10.15620/cdc/20250305009

Alboukadel, K. (2023). *ggpubr: `ggplot2' Based Publication Ready Plots*. In https://CRAN.R-project.org/package=ggpubr

Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020). Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). *PLoS One*, *15*(1), e0227966. https://doi.org/10.1371/journal.pone.0227966

Andresen, M. A., & Boyd, N. (2010). A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. *Int J Drug Policy*, *21*(1), 70–76. https://doi.org/10.1016/j.drugpo.2009.03.004

Aron, A., Toph, A., Hadley, W., Jonathan, M., & Allaire, J. J. (2025). *rsconnect: Deploy Docs, Apps, and APIs to `Posit Connect', `shinyapps.io', and `RPubs'*. In https://CRAN.R-project.org/package=rsconnect

Austin, E. J., Tsui, J. I., Barry, M. P., Tung, E., Glick, S. N., Ninburg, M., & Williams, E. C. (2022). Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma. *J Subst Abuse Treat*, *137*, 108684. https://doi.org/10.1016/j.jsat.2021.108684

Bailey, K., Schecter, A., Eger, W. H., Justin Valasek, C. C. J., Strathdee, S. A., Knox, A., Harvey-Vera, A., Vera, C. F., Goldenberg, S. M., Bazzi, A. R., & Davidson, P. J. (2024). A mixed methods study to inform fatal overdose prevention in San Diego, California: Perspectives from people who use drugs. *Int J Drug Policy*, *133*, 104577. https://doi.org/10.1016/j.drugpo.2024.104577

Bayoumi, A. M., & Zaric, G. S. (2008). The cost-effectiveness of Vancouver's supervised injection facility. *CMAJ*, *179*(11), 1143–1151. https://doi.org/10.1503/cmaj.080808

Behrends, C. N., Leff, J. A., Lowry, W., Li, J. M., Onuoha, E. N., Fardone, E., Bayoumi, A. M., McCollister, K. E., Murphy, S. M., & Schackman, B. R. (2024). Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review. *Value Health*, *27*(5), 655–669. https://doi.org/10.1016/j.jval.2024.02.004

Beletsky, L., Baker, P., Arredondo, J., Emuka, A., Goodman-Meza, D., Medina-Mora, M. E., Werb, D., Davidson, P., Amon, J. J., Strathdee, S., & Magis-Rodriguez, C. (2018). The global health and equity imperative for safe consumption facilities. *Lancet*, *392*(10147), 553–554. https://doi.org/10.1016/S0140-6736(18)31469-7

Bradley, H., Glick, S. N., & Hall, E. W. (2026). Estimated Number of People Who Inject Drugs in the United States, 2022. *Am J Public Health*, *116*(3), 376–379. https://doi.org/10.2105/AJPH.2025.308310

Bradley, H., Hall, E. W., Asher, A., Furukawa, N. W., Jones, C. M., Shealey, J., Buchacz, K., Handanagic, S., Crepaz, N., & Rosenberg, E. S. (2023). Estimated Number of People Who

Inject Drugs in the United States. *Clin Infect Dis*, *76*(1), 96–102. https://doi.org/10.1093/cid/ciac543

Centers for Disease, C., & Prevention. (2024). Fast Facts: HIV in the United States.

Cheema, J. S., Suckow, S., Ramers, C., Loose, P., Tomada, A., Tweeten, S., Stamos-Buesig, T., Abramovitz, D., Eger, W. H., Strathdee, S. A., & Martin, N. K. (2024). Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention Strategies. *Viruses*, *16*(12). https://doi.org/10.3390/v16121819

Ciccarone, D., Holm, N., Ondocsin, J., Schlosser, A., Fessel, J., Cowan, A., & Mars, S. G. (2024). Innovation and adaptation: The rise of a fentanyl smoking culture in San Francisco. *PLoS One*, *19*(5), e0303403. https://doi.org/10.1371/journal.pone.0303403

County of San Diego Health & Human Services Agency. (2024, 2024/05/21). *Harm Reduction Services*. County of San Diego Health & Human Services Agency. https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/hiv_std_hepatitis_branch/Harm_Reduction.html#resources

Day, N., Kaufmann, K., Devoe, D. J. A., Grubac, V., DiMarzo, A., Osmanli, H., Norton, V., Vik, S., Mathew, N., Tanguay, R. L., & Bahji, A. (2026). Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference-in-differences time series. *Addiction*. https://doi.org/10.1111/add.70380

Edzer, P. (2018). Simple Features for R: Standardized Support for Spatial Vector Data. *{The R Journal}*, *10*(1), 439–446. https://doi.org/10.32614/RJ-2018-009

Edzer, P., & Roger, B. (2023). *Spatial Data Science: With applications in R*. Chapman and Hall/CRC. https://doi.org/10.1201/9780429459016

Eger, W. H., Abramovitz, D., Bazzi, A. R., Borquez, A., Vera, C. F., Harvey-Vera, A., Friedman, J. R., & Strathdee, S. A. (2024). Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020-2023. *Drug Alcohol Depend*, *259*, 111318. https://doi.org/10.1016/j.drugalcdep.2024.111318

Elio, C. (2025). *ggnewscale: Multiple Fill and Colour Scales in `ggplot2'*. In https://CRAN.R-project.org/package=ggnewscale

Federal Emergency Management, A. Benefit-Cost Analysis.

Friedman, J., & Shover, C. L. (2023). Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. *Addiction*, *118*(12), 2477–2485. https://doi.org/10.1111/add.16318

Gao, S. S., Yon, M. J. Y., Chen, K. J., Duangthip, D., Lo, E. C. M., & Chu, C. H. (2019). Utilization of a Mobile Dental Vehicle for Oral Healthcare in Rural Areas. *Int J Environ Res Public Health*, *16*(7). https://doi.org/10.3390/ijerph16071234

Gariepy, G., Prowse, R. K. M., Plouffe, R., & Graham, E. (2025). Supervised consumption sites and population-level overdose mortality: a systematic review of recent evidence, 2016-2024. *Health Promot Chronic Dis Prev Can*, *45*(9), 357–366. https://doi.org/10.24095/hpcdp.45.9.02 (Original work published Sites de consommation supervisee et mortalite par surdose a l'echelle de la population : revue systematique des donnees recentes, 2016-2024.)

Garnier, Simon, Ross, Noam, Rudis, Robert, Camargo, Antônio, P., Sciaini, Marco, Scherer, & Cédric. (2024). *viridis(Lite) - Colorblind-Friendly Color Maps for R*. In https://sjmgarnier.github.io/viridis/

Georgia Department of Public Health, D. S. U. (2025a). *Opioid Overdose Surveillance: Preliminary County Report, Georgia, 2023*. https://dph.georgia.gov/epidemiology/drug-surveillance

Georgia Department of Public Health, D. S. U. (2025b). *Stimulant Overdose Surveillance: Preliminary County Report, Georgia, 2023*. https://dph.georgia.gov/epidemiology/drug-surveillance

Georgia Overdose Prevention. (2026). *Georgia Overdose Prevention*. Georgia Overdose Prevention. https://georgiaoverdoseprevention.org/

Granger, N. A., & Hartman, R. L. (2025). *2024 Overdose Deaths in Monroe County*. https://www.monroecounty.gov/files/health/health-action/Overdose%20deaths%20in%20MC%20investigated%20by%20the%20MCOME%202024_color_v2%20(002).pdf

Gregory, R. W., Ben, B., Thomas, L., Arni, M., Bill, V., Genei, R., & Steffen, M. (2023). *gtools: Various R Programming Tools*. In https://CRAN.R-project.org/package=gtools

Gutfraind, A., Boodram, B., Prachand, N., Hailegiorgis, A., Dahari, H., & Major, M. E. (2015). Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. *PLoS One*, *10*(9), e0137993. https://doi.org/10.1371/journal.pone.0137993

Hadley, W. (2007). Reshaping Data with the reshape Package. *Journal of Statistical Software*, *21*(12), 1–20.

Hadley, W., Lionel, H., Thomas Lin, P., Luciani, T. J., Matthieu, D., & Vaudor, L. (2025). *svglite: An `SVG' Graphics Device*. In https://CRAN.R-project.org/package=svglite

Hadley, W., Mara, A., Jennifer, B., Winston, C., Lucy D'Agostino, M., Romain, F., Garrett, G., Alex, H., Lionel, H., Jim, H., Max, K., Thomas Lin, P., Evan, M., Stephan Milton, B., Kirill, M., Jeroen, O., David, R., Dana Paige, S., Vitalie, S.,…Hiroaki, Y. (2019). Welcome to the tidyverse. *Journal of Open Source Software*, *4*(43), 1686. https://doi.org/10.21105/joss.01686

Hadley, W., Thomas Lin, P., & Dana, S. (2025). *scales: Scale Functions for Visualization*. In https://CRAN.R-project.org/package=scales

Harocopos, A., Gibson, B. E., Saha, N., McRae, M. T., See, K., Rivera, S., & Chokshi, D. A. (2022). First 2 Months of Operation at First Publicly Recognized Overdose Prevention Centers in US. *JAMA Netw Open*, *5*(7), e2222149. https://doi.org/10.1001/jamanetworkopen.2022.22149

Irwin, A., Jozaghi, A., Bluthenthal, R. N., & Kral, A. H. (2016). A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug Issues*, *47*(2). https://doi.org/https://doi.org/10.1177/0022042616679829

Irwin, A., Jozaghi, E., Weir, B. W., Allen, S. T., Lindsay, A., & Sherman, S. G. (2017). Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. *Harm Reduct J*, *14*(1), 29. https://doi.org/10.1186/s12954-017-0153-2

Jarlais, D. D., Bobashev, G., Feelemyer, J., & McKnight, C. (2022). Modeling HIV transmission among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the COVID-19 pandemic. *Drug Alcohol Depend*, *238*, 109573. https://doi.org/10.1016/j.drugalcdep.2022.109573

Jeffrey, B. A. (2024). *ggthemes: Extra Themes, Scales and Geoms for `ggplot2'*. In https://CRAN.R-project.org/package=ggthemes

Jeroen, O. (2025). *writexl: Export Data Frames to Excel `xlsx' Format*. In https://CRAN.R-project.org/package=writexl

Jozaghi, E., Reid, A. A., & Andresen, M. A. (2013). A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. *Subst Abuse Treat Prev Policy*, *8*, 25. https://doi.org/10.1186/1747-597X-8-25

Karandinos, G., Unick, J., Ondocsin, J., Holm, N., Mars, S., Montero, F., Rosenblum, D., & Ciccarone, D. (2024). Decrease in injection and rise in smoking and snorting of heroin and synthetic opioids, 2000-2021. *Drug Alcohol Depend*, *263*, 111419. https://doi.org/10.1016/j.drugalcdep.2024.111419

Kennedy, M. C., Hayashi, K., Milloy, M. J., Wood, E., & Kerr, T. (2019). Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLoS medicine*, *16*(11), e1002964. https://doi.org/10.1371/journal.pmed.1002964

Kerr, T., Tyndall, M., Li, K., Montaner, J., & Wood, E. (2005). Safer injection facility use and syringe sharing in injection drug users. *Lancet*, *366*(9482), 316–318. https://doi.org/10.1016/S0140-6736(05)66475-6

Kimball, S., Reynoso, M., McKnight, C., & Des Jarlais, D. (2024). Hepatitis C treatment outcomes among people who inject drugs experiencing unstable versus stable housing: Systematic review and meta-analysis. *PLoS One*, *19*(4), e0302471. https://doi.org/10.1371/journal.pone.0302471

Kral, A. H., Lambdin, B. H., Browne, E. N., Wenger, L. D., Bluthenthal, R. N., Zibbell, J. E., & Davidson, P. J. (2021). Transition from injecting opioids to smoking fentanyl in San Francisco, California. *Drug Alcohol Depend*, *227*, 109003. https://doi.org/10.1016/j.drugalcdep.2021.109003

Kral, A. H., Lambdin, B. H., Wenger, L. D., & Davidson, P. J. (2020). Evaluation of an Unsanctioned Safe Consumption Site in the United States. *N Engl J Med*, *383*(6), 589–590. https://doi.org/10.1056/NEJMc2015435

Kyle, W., & Matt, H. (2025). *tidycensus: Load US Census Boundary and Attribute Data as `tidyverse' and `sf'-Ready Data Frames*. In https://CRAN.R-project.org/package=tidycensus

Liu, S., Barnett, P. G., Holodniy, M., Lo, J., Joyce, V. R., Gidwani, R., Asch, S. M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2016). Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. *MDM Policy Pract*, *1*(1). https://doi.org/10.1177/2381468316671946

Maintaining Drug-Involved Premises, 21 U.S. Government Publishing Office § 856. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section856

Mark, P., Bob, R., Robin, L., & Maëlle, S. (2017). osmdata. *Journal of Open Source Software*, *2*(14), 305. https://doi.org/10.21105/joss.00305

Marshall, B. D. L., Milloy, M. J., Wood, E., Montaner, J. S. G., & Kerr, T. (2011). Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet*, *377*(9775). https://doi.org/10.1016/S0140-6736(10)62353-7

Marshall, T., Abba-Aji, A., Tanguay, R., & Greenshaw, A. J. (2021). The Impact of Supervised Consumption Services on Fentanyl-related Deaths: Lessons Learned from Alberta's Provincial Data. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie*, *66*(12), 1096–1098. https://doi.org/10.1177/0706743721999571

Monroe County Department of Public Health. (2026). *NaloxBox Locations Map*. Monroe County, New York. https://www.monroecounty.gov/narcan

New York State Department of Health. (2026). Opioid Data Dashboard: County Reports.

New York State Department of Health, O. o. D. U. H. (2024, 2024/07). *Syringe Access & Drug User Health Hub Programs*. New York State Department of Health. https://www.health.state.ny.us/diseases/aids/consumers/prevention/syringe_access.htm

Office of National Drug Control, P. (2025). San Diego - Imperial Valley High Intensity Drug Trafficking Area (HIDTA).

OnPoint, N. Y. C. (2025). Overdose Prevention Centers.

Panagiotoglou, D., & Lim, J. (2022). Using synthetic controls to estimate the population-level effects of Ontario's recently implemented overdose prevention sites and consumption and treatment services. *The International Journal on Drug Policy*, *110*, 103881. https://doi.org/10.1016/j.drugpo.2022.103881

Paolo Di, L. (2024). *usmap: US Maps Including Alaska and Hawaii*. In https://CRAN.R-project.org/package=usmap

Pouget, E. R., Hagan, H., & Des Jarlais, D. C. (2012). Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. *Addiction*, *107*(6), 1057–1065. https://doi.org/10.1111/j.1360-0443.2011.03765.x

Rammohan, I., Gaines, T., Scheim, A., Bayoumi, A., & Werb, D. (2024). Overdose mortality incidence and supervised consumption services in Toronto, Canada: an ecological study and spatial analysis. *The Lancet Public Health*, *9*(2), e79–e87. https://doi.org/10.1016/S2468-2667(23)00300-6

Reuben, D. B., Bassett, L. W., Hirsch, S. H., Jackson, C. A., & Bastani, R. (2002). A randomized clinical trial to assess the benefit of offering on-site mobile mammography in addition to health education for older women. *AJR Am J Roentgenol*, *179*(6), 1509–1514. https://doi.org/10.2214/ajr.179.6.1791509

Robinson, T., Farrokhyar, F., & Fischer, B. (2024). The associations of supervised consumption services with the rates of opioid-related mortality and morbidity outcomes at the public health unit level in Ontario (Canada): A controlled interrupted time-series analysis. *Drug and Alcohol Review*, *43*(7), 1880–1891. https://doi.org/10.1111/dar.13921

Robinson, T., Farrokhyar, F., & Fischer, B. (2024). The associations of supervised consumption services with the rates of opioid-related mortality and morbidity outcomes at the public health unit level in Ontario (Canada): A controlled interrupted time-series analysis. *Drug Alcohol Rev*, *43*(7), 1880–1891. https://doi.org/10.1111/dar.13921

Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E. (2015). The lifetime medical cost savings from preventing HIV in the United States. *Med Care*, *53*(4), 293–301. https://doi.org/10.1097/MLR.0000000000000308

Scott, C., Andy, T., & Michael, M. (2023). *geojsonio: Convert Data from and to `GeoJSON' or `TopoJSON'*. In https://CRAN.R-project.org/package=geojsonio

Sergei, I. (2024). *tictoc: Functions for Timing R Scripts, as Well as Implementations of ``Stack'' and ``StackList'' Structures*. In https://CRAN.R-project.org/package=tictoc

Stepanova, M., & Younossi, Z. M. (2017). Economic Burden of Hepatitis C Infection. *Clin Liver Dis*, *21*(3), 579–594. https://doi.org/10.1016/j.cld.2017.03.012

Suen, L. W., Wenger, L. D., Morris, T., Majano, V., Davidson, P. J., Browne, E. N., Ray, B., Megerian, C. E., Lambdin, B. H., & Kral, A. H. (2023). Evaluating oxygen monitoring and administration during overdose responses at a sanctioned overdose prevention site in San Francisco, California: A mixed-methods study. *Int J Drug Policy*, *121*, 104165. https://doi.org/10.1016/j.drugpo.2023.104165

Tanz, L. J., Miller, K. D., Dinwiddie, A. T., Gladden, R. M., Asher, A., Baldwin, G., Nesbit, B., & O'Donnell, J. (2025). Drug Overdose Deaths Involving Stimulants - United States, January 2018-June 2024. *MMWR Morb Mortal Wkly Rep*, *74*(32), 491–499. https://doi.org/10.15585/mmwr.mm7432a1

Team, R. C. (2025). *R: A Language and Environment for Statistical Computing*. In R Foundation for Statistical Computing. https://www.R-project.org/

Teun van den, B. (2025). *legendry: Extended Legends and Axes for `ggplot2'*. In https://CRAN.R-project.org/package=legendry

Tyson, B., Matt, D., Arun, S., Jan, G., Michael, C., Toby, H., Benjamin, S., & Ivan, K. (2025). *data.table: Extension of `data.frame'*. In https://CRAN.R-project.org/package=data.table

U. S. Department of Health & Human Services. (2026a, 2022). *Fulton County HIV Data America's HIV Epidemic Analysis Dashboard (AHEAD)*. U.S. Department of Health and Human Services, Office of Infectious Disease and HIV/AIDS Policy. https://ahead.hiv.gov/georgia/fulton_county/

U. S. Department of Health & Human Services. (2026b). *San Diego HIV Data America's HIV Epidemic Analysis Dashboard (AHEAD)*. America's HIV Epidemic Analysis Dashboard (AHEAD). https://ahead.hiv.gov/california/san_diego_county

United States v. Safehouse, 985 225–272 (2021). https://law.justia.com/cases/federal/appellate-courts/ca3/19-3835/19-3835-2021-01-12.html

Winston, C. (2021). *shinythemes: Themes for Shiny*. In https://CRAN.R-project.org/package=shinythemes

Winston, C., Joe, C., Allaire, J. J., Carson, S., Barret, S., Yihui, X., Jeff, A., Jonathan, M., Alan, D., & Barbara, B. (2024). *shiny: Web Application Framework for R*. In https://CRAN.R-project.org/package=shiny

Wood, E., Kerr, T., Small, W., Li, K., Marsh, D. C., Montaner, J. S., & Tyndall, M. W. (2004). Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. *CMAJ*, *171*(7), 731–734. https://doi.org/10.1503/cmaj.1040774

Wood, E., Tyndall, M. W., Zhang, R., Montaner, J. S., & Kerr, T. (2007). Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. *Addiction*, *102*(6), 916–919. https://doi.org/10.1111/j.1360-0443.2007.01818.x

Yeung, M. E. M., Lee, C. H., Hartmann, R., & Lang, E. (2023). Opioid-related emergency department visits and deaths after a harm-reduction intervention: a retrospective observational cohort time series analysis. *CMAJ Open*, *11*(3), E537–E545. https://doi.org/10.9778/cmajo.20220104

Yihui, X., Joe, C., & Xianying, T. (2024). *DT: A Wrapper of the JavaScript Library `DataTables'*. In https://CRAN.R-project.org/package=DT

Counties with highest number of PWID
California-Los Angeles County
Illinois-Cook County
Texas-Harris County
Arizona-Maricopa County
California-San Diego County
California-Orange County
Florida-Miami-Dade County
New York-Kings County
Texas-Dallas County
New York-Queens County
California-Riverside County
Washington-King County
Nevada-Clark County
California-San Bernardino County
Texas-Tarrant County
Florida-Broward County
Texas-Bexar County
California-Santa Clara County
New York-New York County

Michigan-Wayne County
California-Alameda County
Massachusetts-Middlesex County
Pennsylvania-Philadelphia County
Florida-Palm Beach County
California-Sacramento County
New York-Suffolk County
Florida-Hillsborough County
Florida-Orange County
New York-Nassau County
New York-Bronx County
Texas-Travis County
Ohio-Franklin County
Michigan-Oakland County
Pennsylvania-Allegheny County
Minnesota-Hennepin County
Ohio-Cuyahoga County
California-Contra Costa County
North Carolina-Wake County
Virginia-Fairfax County

Utah-Salt Lake County
North Carolina-Mecklenburg County
Georgia-Fulton County
Arizona-Pima County
Texas-Collin County
Maryland-Montgomery County
Florida-Pinellas County
Hawaii-Honolulu County
New York-Westchester County
Florida-Duval County
Missouri-St. Louis County

674 *Supplementary table 1: Counties with highest number of PWID*

675

Counties with highest deaths per capita
Texas-Borden County
New Mexico-Rio Arriba County
Kentucky-Lee County
Nebraska-Logan County
Texas-Kent County
New Mexico-Taos County

Alaska-Lake and Peninsula County
California-Lake County
Kentucky-Powell County
West Virginia-Logan County
Maryland-Baltimore (city) County
West Virginia-Cabell County
Kansas-Greeley County
Kentucky-Estill County
West Virginia-Lincoln County
Kentucky-Knott County
Kentucky-Breathitt County
West Virginia-Mercer County
California-Del Norte County
Kentucky-Boyd County
Arizona-La Paz County
West Virginia-Mingo County
Texas-Karnes County
Tennessee-Roane County
Texas-Irion County
Louisiana-Washington County

Washington-Okanogan County
Alaska-Anchorage County
Kentucky-Clay County
Tennessee-Morgan County
Tennessee-DeKalb County
Washington-Grays Harbor County
West Virginia-McDowell County
Alabama-Walker County
Virginia-Buchanan County
Kentucky-Rockcastle County
Missouri-St. Louis (city) County
Texas-Dickens County
North Dakota-Golden Valley County
California-Butte County
California-Alpine County
Tennessee-Cocke County
New Mexico-Santa Fe County
Nebraska-Garden County
Washington-Spokane County
Kentucky-Harlan County

Colorado-Cheyenne County
Pennsylvania-Philadelphia County
Tennessee-Campbell County
Utah-Piute County

Supplementary table 2: Counties with highest deaths per capita

OPC Data Explorer

sportiellomike.shinyapps.io/OPC-data-explorer/ 80%

OPC Data Explorer

Select State:

Georgia

Select County:

Fulton County

Select Year:

2025

Select what percent of injections happent at OPC:

1

Select Column for Plot Color:

cumulativelivessaved

Select Transformation:

log2(1+value)

Legend Label:

Cumulative deaths averted

Legend Text Size:

12

Legend Minimum:

0

Legend Maximum:

Plots | Local Results | National Results | Data

Plots for subset of data selected on the left